Lena Friberg, PhD, is a professor in pharmacometrics at Uppsala University, Sweden. She received her PhD in pharmacokinetics and drug therapy in 2003 from Uppsala University and spent nearly 2 years as a postdoc at University of Queensland, Australia.
Her research focuses on development of population pharmacokinetic (PK) and pharmacodynamic (PD) models that increase the understanding of drugs’ desired effects and adverse effects, with a focus on anticancer drugs and antibiotics. She has received the Giorgio Segré Prize from EUFEPS for distinction in the field of PK and PD, serves as the chair of the scientific committee for the annual PAGE meeting on pharmacometrics and is deputy editor in chief for the journal CPT: Pharmacometrics & Systems Pharmacology. She has published over 90 peer reviewed papers. Her current research is focused on development of predictive PKPD-models useful for quantitative translation of longitudinal drug effects from preclinical information to patients and from early to late clinical development. In the oncology area relationships between biomarkers, different adverse effects, tumor size, tumor activity and survival are evaluated to allow for improved understanding of correlations between the variables and for investigating consequences of different dosing regimens, both on a population and an individual level.